Acute Care Syndromic Testing Market Positioned for Explosive Growth, BIS Research Report Forecasts $8.44 Billion Market Value by 2033 


BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Acute Care Syndromic Testing Market – A Global and Regional Analysis.

Market Analysis: Trends, Data, and Growth Projections: 

The acute care syndromic testing market includes panels and instruments that can test for more than one type of pathogen and specific instruments used to perform these tests. These instruments are predominantly polymerase chain reaction-based testing kits, panels, or assays. The most common syndromic testing panels include respiratory, gastrointestinal, genitourinary, and tropical diseases, among others.

According to this study, the acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033.
The global acute care syndromic testing market has witnessed significant growth, with the increasing prevalence of infectious diseases and the formulation of various plans to mitigate future outbreakspandemics such as COVID-19. Furthermore, global warming and the detection of new infectious diseases around the world are also influencing market growth.

Report Focus and Methodology: 

The acute care syndromic testing market report provides a credible global and regional market analysis and forecast for 2023-2033. The report profiles existing and upcoming products, types, applications, end users, and key players in the market.

BIS Research follows an effective market intelligence methodology, comprising a crucial 15-step process. Data is captured from reliable intelligent sources such as expert interviews, patents, web analytics, scholarly articles, scientific publications, and research and development literature.

BIS follows the Deep Tech M-A-P™ approach, which includes market, application, and product, within the syndicated and custom research projects.

M- The Market section covers industry overview, business dynamics, competitive benchmarks, and company profiles. To provide insights to enter, expand, or exit markets globally, regionally, or locally.

A- The Application section dives deep into product analyses, technology insights, use cases, and user types. This data is backed by precise market estimates and forecasts.

P- The Product section covers products, parts, technologies and materials. Companies looking to drive an innovative agenda need information about product definitions, demand analysis, technology benchmarking and roadmaps, patents, as well as pricing analysis.

The following factors are responsible for the increase in demand for the Acute Care Syndromic Testing Market: 

  • Faster Results Acquired with Syndromic Tests 
  • Increasing Incidence of Infectious Diseases 
  • Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing 


Market Segments 

The market is segmented based on disease type, target, sample type, end users, and regions. This comprehensive analysis provides insights into disease patterns, targets, and testing methods across diverse sample types. The segmentation facilitates tailored approaches for healthcare providers and researchers.

Major Industry Leaders in the Acute Care Syndromic Testing Market: 

The companies profiled have been selected based on input gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some of the established names in the market are: 

Abbott Laboratories, Becton, Dickinson and Company, Biocartis NV, bioMérieux SA (BioFire Diagnostics), Danaher Corporation (Cepheid, Inc.), DiaSorin S.p.A (Luminex Corporation), Eurofins Scientific (Eurofins Viracor), Karius, Laboratory Corporation of America Holdings., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, SpeeDx, Thermo Fisher Scientific Inc.

Recent Developments in the Acute Care Syndromic Testing Market: 

  • Innovative molecular diagnostic tests enable simultaneous detection of major respiratory viruses, including SARS-CoV-2, flu A, flu B, and RSV. 
  • User-friendly at-home test detects COVID-19 and flu, suitable for children as young as two years old.
  •  Collaboration with over 100 global scientists to utilize diagnostic testing and data science technologies for outbreak mitigation.
  • Medline Industries to distribute MDx-3000 system for diagnosing gastrointestinal and respiratory infections, along with Analyte Specific Reagents (ASRs).
  • QIAGEN N.V. Unveils Groundbreaking QIAstat-Dx Syndromic Testing Solution in Japan (April 2023). 
  • The Japanese market gains access to QIAstat-Dx, capable of detecting over 20 respiratory pathogens, including SARS-CoV-2, from a single sample.


Analyst’s Take on the Market Projection: According to Prateeksha Singh, Lead Analyst – BIS Research, “With the growing incidence of infectious diseases, acute care syndromic testing is expected to relieve the pressure of hospitals from these diseases with earlier diagnosis and interventions. The Asia-Pacific acute care syndromic testing market, particularly, is expected to register significant growth during the forecast period 2023-2033.”

About BIS Research

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.

See Campaign:

Contact Information:

Head of Marketing Email: [email protected] BIS Research Inc. 39111 PASEO PADRE PKWY STE 313, FREMONT, CA 94538-1686 Visit our Blog @ Get Expert Insights @ Connect with us on LinkedIn @ Connect with us on Twitter@

Extended Distribution, Reportedtimes, BNN, iCN Internal Distribution, Research Newswire, English